Pancreatic Cancer Research

Clinical trialPhase 1Active not recruiting

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Outcome
Ongoing
Phase
Phase 1
Status
Active not recruiting
Study type
Interventional
Start
19 April 2023
Listed end
31 October 2026
Enrollment
130 participants
Sites
18
Primary outcomes
Incidence of Dose Limiting Toxicities (DLT); Incidence of Adverse Events (AE) and Serious Adverse Events (SAE); Incidence of Clinically Significant Laboratory Abnormalities
Sponsor type
Industry
Results posted
No
Last update
1 June 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.